Related Experiment Video
Updated: Jun 25, 2026
09:57
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Outcome in elderly acute myeloid leukaemia
1Department of Haematology, University Hospital Galway, Newcastle Road, Galway. hasko11@gmail.com
Irish Medical Journal
|February 12, 2009
Summary
Elderly patients with acute myeloid leukemia (AML) receiving intensive chemotherapy showed improved outcomes. Survival rates varied by age group, with significant differences noted between diagnosis periods for those aged 60-69.
Area of Science:
- Hematology
- Oncology
- Geriatric Medicine
Background:
- Acute myeloid leukemia (AML) is a significant health concern, particularly in the elderly population.
- Understanding treatment patterns and outcomes in older AML patients is crucial for improving care.
- Previous studies have highlighted disparities in treatment intensity and survival based on age.
Purpose of the Study:
- To analyze the characteristics and outcomes of elderly patients diagnosed with acute myeloid leukemia (AML).
- To compare the efficacy of intensive chemotherapy versus other treatments in this demographic.
- To evaluate changes in AML incidence and survival rates over two distinct diagnostic periods.
Main Methods:
- Retrospective review of 79 newly diagnosed acute myeloid leukemia (AML) patients admitted between 1996 and 2005.
- Analysis of patient demographics, treatment received (intensive chemotherapy vs. other), and survival data.
- Statistical comparison of AML rates and overall survival between different age groups and diagnostic periods.
Main Results:
- The overall acute myeloid leukemia (AML) rate for patients aged 60 years and above receiving intensive chemotherapy was 52.9%.
- Patients aged 60-69 had a significantly higher AML rate in the later diagnostic period (2001-2005) compared to 1996-2000 (P = 0.018).
- Median overall survival was significantly longer for patients receiving intensive chemotherapy (9.73 months) versus other treatments (3.6 months) (P < 0.0001).
- A significant survival difference was observed in patients aged 80 years and above between the two diagnostic periods (3.0 vs. 0.63 months, P = 0.023).
Conclusions:
- Intensive chemotherapy significantly improves survival in elderly acute myeloid leukemia (AML) patients.
- Treatment outcomes and incidence rates for AML in the elderly have shown some changes over time, with variations across age subgroups.
- This study provides valuable insights into the management and prognosis of AML in older adults within a specific clinical setting.
